BIM
ACAD icon

Bogle Investment Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Bogle Investment Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-270,715
Closed -$4.13M – 265
2018
Q2 		$4.13M Buy
+270,715
New +$4.83M 0.3% 109

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Bogle Investment Management's ACAD Position: Q3 2018 in Review

Bogle Investment Management sold out of Acadia Pharmaceuticals (ACAD) in Q3 2018, closing a stake of 270,715 shares — an estimated $4.13M sold.

Bogle Investment Management first reported a position in ACAD in Q2 2018 and held it in 1 quarter. The position peaked at $4.13M in Q2 2018. 184 funds tracked by Wall St. Rank hold ACAD as of Q3 2018.

  • Bogle Investment Management reported no remaining Acadia Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Bogle Investment Management sold 270,715 Acadia Pharmaceuticals shares in Q3 2018, an estimated $4.13M.
  • Bogle Investment Management first reported a position in Acadia Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Bogle Investment Management's Acadia Pharmaceuticals position peaked at $4.13M in Q2 2018.
  • 184 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2018.

Based on Bogle Investment Management's 13F filing for Q3 2018, filed 13 Nov 2018.